Bioresorbable Scaffold

Drug-coated Balloon

Computational design

Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable peripheral stents and drug coated balloons, has announced that on 17th November 2023 it has obtained EN ISO 13485:2016 certification for its Quality Management System, following a successful audit by BQAI (Ireland).

Design, development, pre-clinical and clinical evaluation of bioresorbable drug-eluting stents (scaffolds), drug-coated balloons intended to treat vascular disease, and related technologies such as coating and material enhancement.

ISO 13485 is the internationally accepted standard a medical device organisation can implement to demonstrate compliance with MedTech legislations.

Nial Bullett, Arterius’ Operations Manager, commented

“Obtaining ISO 13485 Certification for our Arterius QMS will ensure recognition for Arterius’ compliance with ISO 13485 requirements and demonstrate confidence in our consistent design and development of our innovative medical device development products”.

Kadem Al-Lamee, Chief Technical Officer of Arterius, commented:

“Achieving this ISO 13485 certification gives confidence to our investors and stakeholders that we are committed to ensuring excellent product design and development of our products and, ultimately, ensuring patient safety”.

Arterius Ltd receives ISO 13485 Certification

Arterius Limited
Mayesbrook House
Lawnswood Business Park
Redvers Close
Leeds
LS16 6QY

Homepage

Home

Technology

About

About us

Team

Newspage

News

Publications

Contact

Contact us

Technologies

Arterius CTO, Dr Kadem Al-Lamee, presented on the company's bioresorbable scaffold technology at the Annual World Congress of Smart Materials, 22–24 July 2023 in Barcelona, Spain. Further details on the conference are available at 

Arterius presents at World Congress of Smart Materials 2023

Arterius CTO, Dr Kadem Al-Lamee, will present on Arterius' approach to drug-coated balloons for use to treat peripheral arterial disease at the 4th International Conference on Biomaterials & Biodevices in Rome, Italy, November 16–17 2023. Details for the conference are available 

Arterius to present at BioMat 2023

Arterius Limited, a Leeds UK-based company developing innovative medical devices with a focus on next generation bioresorbable peripheral stents and drug coated balloons, has announced that it has appointed Gerard Harper as Chief Financial Officer. In this role, Gerard will help Arterius to develop and drive the commercial strategy for the successful launch of a suite of innovative technologies in its current pipeline.

Gerard brings extensive experience in medical devices and healthcare companies gained through roles in investment banking, venture capital and early-stage companies. Gerard held finance and commercial roles at Quanta Dialysis Technologies for over six years helping to guide its development into one of the most prominent emerging
medical device companies in the UK.

Gerard will build on the success of Kadem Al-Lamee, co-founder and Chief Technical Officer who is leading the development of the existing product pipeline and IP and of new applications and technologies.

“I want to welcome Gerard to Arterius as he brings a wealth of leadership experience in commercial development and investment in life sciences. His track record will be invaluable as Arterius continues its journey through the development of innovative technologies in the MedTech sector.”

“I am delighted to join Arterius at this exciting time as it aims to bring two class-leading product platforms to market, with the capability to transform the management of peripheral arterial disease”.

To learn more visit: www.arterius.co.uk





Arterius appoints Gerard Harper as CFO

Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Christopher (Chris) Meredith as Chair of the Board of Directors. In this role, Chris will manage the Board and help Arterius develop and drive the commercial strategy for the successful launch of a suite of innovative technologies in its current pipeline.

Chris succeeds Alistair Taylor who passed away on 12th December 2021. Alistair was the co-founder of Arterius and played a major role to move the business forward. Alistair, with over 47 years of experience in the Pharmaceutical and Medical Device Industries in Europe and the US, raising over $300 million in public and private fund raisings, helped Arterius progress successfully from inception to a point where the technology was ready for first in man trials.

With over 30 years of industry experience, Chris is currently Group Chief Executive Officer of Advanced Medical Solutions Group plc (AMS), a role he has held since 2011. He joined AMS as Group Commercial Director in July 2005 following a successful 18-year career in international healthcare sales, marketing and business development. He joined AMS as a small loss making wound care company and has been instrumental in helping lead the company to its current status as a highly profitable, AIM listed, global tissue healing company. His experience prior to joining AMS covered business-to-business contract manufacturing, product development and clinical research, as well as branded product sales all within the medical device, pharmaceutical or consumer healthcare markets.

Mr Meredith was appointed as a Non-Executive Chair of Arterius Limited in January 2022. 

"I am looking forward to working with Kadem, the existing Board members and the entire team at Arterius. I have been hugely impressed with everyone I have met so far and what has already been achieved. Arterius has developed an exciting range of new products and I am excited by the prospects the next few years have in store for the company."

Kadem Al-Lamee, Chief Executive Officer of Arterius

"I am delighted to welcome Chris to Arterius, particularly at a point where we are rapidly progressing towards commercialisation. His considerable experience in successfully growing medical device businesses will make a significant difference and add value to the company and for our shareholders. I would also like to remember Alistair for his commitment to Arterius and his guidance and support, which has enabled us to get to where we are today."

Arterius appoints Chris Meredith as Chair

Arterius to present a poster at the Charing X International Symposium in London, 25–27 April 2023 entitled 'Development of Innovative Bioresorbable Stents to Treat Patients with Critical Limb Ischaemia in Below-the-Knee Peripheral Artery Disease'. The poster chatacterises Arterius' bioresorbable scaffold and is available to download. 

Terms & Conditions

The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.

Unauthorised use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time, this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

Your use of this website and any dispute arising out of such use of the website is subject to the laws of England and Wales.